Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog

Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) reported positive exploratory market research supporting the commercial opportunity for Neonorm Dog, a plant-based, non-prescription product designed to support normal stool consistency and GI fluid balance in dogs. Neonorm Dog extends Jaguar's existing Neonorm franchise, which currently includes Neonorm Foal and Neonorm Calf.

In a directional survey of 33 veterinary oncologists, nearly 90% viewed the Neonorm Dog concept as clinically relevant, almost 80% said they would likely recommend it for selected canine oncology patients, and 69% would recommend owners keep it at home for early loose stool. In an exploratory survey of 18 dog owners, 83% found the concept very or extremely appealing and 94% would definitely or probably purchase the product. Jaguar is finalizing packaging, labeling, and launch preparations and expects to offer Neonorm Dog via select online and animal health retail channels, including Amazon and Chewy, to broaden its companion animal footprint.

Positive

• Veterinary oncologist interest: nearly 90% viewed Neonorm Dog as clinically relevant
• Potential recommendation: almost 80% of 33 oncologists likely to recommend for selected canine oncology patients
• At-home use support: 69% of oncologists likely to recommend owners keep Neonorm Dog on hand
• Consumer appeal: 83% of 18 surveyed dog owners found the concept very or extremely appealing
• Purchase intent: 94% of surveyed dog owners would definitely or probably buy Neonorm Dog
• Planned distribution: expected availability via Amazon, Chewy, and other online/retail animal health channels

Negative

• Market research based on small samples: 33 veterinary oncologists and 18 dog owners
• Company characterizes surveys as exploratory and directional, not statistically representative

Market reaction after Neonorm Dog market research: JAGX -3.55% in the Jul 28 session

-3.55%

1 alert

-3.55% Session close to close

$4.50M Market Cap

0.8x Rel. Volume

In the Jul 28 session, JAGX declined 3.55%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

1.35% was JAGX’s 24-hour reaction to a June 30 data presentation, adding a positive historical refer...

Analysis

1.35% was JAGX’s 24-hour reaction to a June 30 data presentation, adding a positive historical reference. This announcement is earlier-stage market research; its stated small, directional design and active S-3 shelf are the key watchpoints.

Key Figures

Veterinary oncologist survey size: 33 veterinary oncologists Clinical relevance assessment: nearly 90% Recommendation likelihood: almost 80% +4 more

7 metrics

Veterinary oncologist survey size 33 veterinary oncologists Directional survey

Clinical relevance assessment nearly 90% Responding veterinary oncology specialists

Recommendation likelihood almost 80% Responding veterinary oncology specialists

At-home recommendation likelihood 69% Veterinary oncology specialists

Dog-owner survey size 18 dog owners Exploratory consumer survey

Concept appeal 83% Dog-owner respondents found the concept very or extremely appealing

Purchase intent 94% Dog-owner respondents indicated definite or probable purchase

Historical Context

5 past events · Latest: Jul 22 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 22	Compassionate use	Positive	+5.6%	Additional infant received crofelemer through compassionate use for intestinal failure
Jun 30	Clinical data presentation	Positive	+1.4%	ESPGHAN presentation described long-term parenteral support reductions with crofelemer
Jun 25	Preferred stock conversion	Neutral	+1.9%	Series O preferred stock converted into common shares at a specified rate
Jun 23	FDA application submission	Positive	-1.9%	New Animal Drug Application submitted for full crofelemer approval in dogs
Jun 22	Strategic alternatives	Positive	+16.0%	Board explored alternatives alongside targeted NDA filing for rare intestinal failure

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior selected news events were generally followed by positive 24-hour reactions, with one negative divergence after an FDA filing.

Key Terms

gi fluid balance, veterinary oncologists, standardized botanical extract, supportive care, +1 more

5 terms

gi fluid balance medical

"designed to support normal stool consistency and GI fluid balance in dogs"

The balance of fluids entering, being secreted by, absorbed from, and leaving the gastrointestinal (GI) tract; it describes how the gut manages water and electrolytes during digestion, disease, or treatment. For investors, changes in GI fluid balance matter because they affect how drugs are absorbed, tolerated and dosed, influence outcomes in trials for GI or systemic therapies, and can drive demand for treatments or supportive care—think of the gut as a plumbing system that must stay calibrated for medicines and patients to work as intended.

veterinary oncologists medical

"directional survey of 33 veterinary oncologists"

Veterinary oncologists are specialized veterinarians who diagnose and treat cancer in animals, using tools such as imaging, surgery, chemotherapy, radiation, and targeted therapies. For investors, they matter because they drive demand for veterinary drugs, diagnostics, clinical trials, and specialty services—similar to how human oncologists influence the market for cancer treatments—so their clinical choices, referral patterns, and involvement in research can affect revenues, regulatory paths, and adoption of new veterinary oncology products.

standardized botanical extract technical

"contain a standardized botanical extract derived from the sustainably harvested"

A standardized botanical extract is a plant-derived ingredient manufactured so each batch contains a consistent, measured amount of one or more key chemical compounds thought to provide the plant’s effects. Like a recipe that guarantees the same flavor every time, standardization controls variability from growing conditions and processing, which matters to investors because it affects product quality, regulatory compliance, manufacturing predictability, and the commercial reliability of ingredients used in supplements, foods, or medicines.

supportive care medical

"designed to help support normal stool consistency and complement supportive care"

Medical care and treatments that manage symptoms, side effects, and overall well‑being rather than trying to cure the underlying disease; examples include pain control, nutrition support, infection prevention, and therapies to reduce treatment side effects. It matters to investors because demand for supportive care products and services influences healthcare spending, product pipelines, regulatory approvals, and revenue streams—think of it like maintenance for a machine that keeps other therapies usable and patients healthier while primary treatment continues.

directional survey technical

"The results of our directional survey of 33 veterinary oncologists"

A directional survey asks a group of people whether they expect a specific metric or outcome to move up, down, or stay the same, rather than measuring exact amounts. It acts like a quick thermometer of future sentiment—similar to asking neighbors whether traffic will be heavier tomorrow—helping investors and analysts spot trends or shifts in expectations that can signal changes in demand, prices, or business conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Neonorm^® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI fluid balance in dogs

Jaguar expects to make Neonorm Dog available through both Amazon and Chewy

SAN FRANCISCO, CA / ACCESS Newswire / July 28, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that the findings of exploratory surveys of dog owners and veterinary oncologists support the company's commercial opportunity for Neonorm Dog, a new extension of Jaguar's Neonorm franchise for companion animals. Neonorm Dog is designed to provide dog owners with access to a plant-based, non-prescription product intended to support normal stool consistency and GI fluid balance in dogs. The Neonorm franchise currently includes Neonorm Foal and Neonorm Calf, plant-based products developed to support proper hydration and bowel health in pre-weaned foals and calves. Neonorm products contain a standardized botanical extract derived from the sustainably harvested Croton lechleri tree, which acts locally in the gut.

"The results of our directional survey of 33 veterinary oncologists reinforce our belief that there is a meaningful unmet need for additional non-antibiotic, locally acting digestive support options for dogs with loose or watery stool that are designed to help support normal stool consistency and complement supportive care," said Ian Wendt, Jaguar's Chief Business Officer. "It is encouraging that nearly 90% of responding veterinary oncology specialists viewed the Neonorm Dog concept as clinically relevant, and that almost 80% indicated they would be likely to recommend it for selected canine oncology patients if available. 69% say they would be somewhat or very likely to recommend that dog owners keep Neonorm Dog at home for early loose stool. We view this feedback as important guidance as we continue preparing for our planned launch of Neonorm Dog."

"In our exploratory survey of 18 dog owners conducted to explore consumer attitudes, behaviors, and purchase intent for Neonorm Dog, dog owners responded positively to the Neonorm Dog concept, with participants expressing strong interest in a science-informed digestive support supplement designed to help support stool-firming. 83% of respondents found the Neonorm Dog concept very or extremely appealing, and 94% indicated they would definitely or probably purchase the product," Wendt said. "While this was a small, directional survey and not intended to be statistically representative, the findings reinforce our confidence in the unmet need Neonorm Dog is designed to address, and the findings will help guide our messaging, channel strategy, and future market validation efforts as we prepare for the commercial launch of the product."

"We are encouraged by the enthusiasm we saw in this early research. Participants consistently reinforced themes that align with our product strategy - including demand for a science-informed digestive support product that owners can keep on hand and use at the first sign of digestive upset," said Lisa Conte, Jaguar's founder, president and CEO. "Neonorm Dog is designed as a science-backed replacement for uncertain home remedies for digestive support that owners can keep on hand before symptoms start."

Jaguar is working on completing final packaging, labeling, and commercial launch preparations for Neonorm Dog and expects to make the product available through select online and animal health retail channels, including Amazon and Chewy. The launch of Neonorm Dog is intended to broaden Jaguar's commercial footprint in the companion animal market and extend consumer awareness of the Neonorm brand. Dogs represent one of the largest companion animal populations in the United States and Europe, and Jaguar believes Neonorm Dog may create an opportunity to reach pet owners, veterinarians, and animal health retailers seeking non-antibiotic, plant-based options to support digestive health.

About Neonorm

Neonorm is Jaguar's non-prescription animal-health franchise of plant-based products developed to support digestive health, hydration, and normal stool quality in animals. Existing Neonorm products include Neonorm Foal and Neonorm Calf. Neonorm Dog is not intended to diagnose, treat, cure, or prevent any disease and is not intended as a substitute for veterinary care.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. Jaguar family companies Napo Pharmaceuticals, Inc. (Napo) and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements related to Jaguar's planned launch of Neonorm Dog, and Jaguar's expectation that Neonorm Dog will be available through select online and animal health retail channels, including Amazon and Chewy. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

hello@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

FAQ

What is Neonorm Dog from Jaguar Health (NASDAQ:JAGX) and what does it do?

Neonorm Dog is a plant-based, non-prescription supplement designed to support normal stool consistency and GI fluid balance in dogs. According to Jaguar Health, it uses a standardized Croton lechleri botanical extract that acts locally in the gut and extends the existing Neonorm animal-health franchise.

What market research supports the Neonorm Dog launch by Jaguar Health (JAGX)?

Jaguar Health reports exploratory surveys of 33 veterinary oncologists and 18 dog owners supporting Neonorm Dog’s commercial opportunity. According to Jaguar Health, nearly 90% of oncologists saw the concept as clinically relevant, and 94% of surveyed dog owners would definitely or probably purchase the product.

How interested are veterinarians in recommending Neonorm Dog from Jaguar Health (JAGX)?

In Jaguar Health’s directional survey, almost 80% of 33 veterinary oncology specialists said they would likely recommend Neonorm Dog for selected canine oncology patients. According to Jaguar Health, 69% would be somewhat or very likely to recommend owners keep it at home for early loose stool episodes.

What did dog owners say about buying Neonorm Dog from Jaguar Health (NASDAQ:JAGX)?

In an exploratory survey of 18 dog owners, participants responded positively to the Neonorm Dog concept. According to Jaguar Health, 83% found it very or extremely appealing, and 94% indicated they would definitely or probably purchase the science-informed digestive support supplement for their dogs.

When and where will Neonorm Dog from Jaguar Health (JAGX) be available?

Jaguar Health is completing final packaging, labeling, and commercial launch preparations for Neonorm Dog. According to Jaguar Health, the company expects to make the product available through select online and animal health retail channels, including Amazon and Chewy, expanding its companion animal market presence.

Is Neonorm Dog from Jaguar Health (JAGX) a medicine or a supplement?

Neonorm Dog is a non-prescription, plant-based digestive support product, not a disease treatment. According to Jaguar Health, it is not intended to diagnose, treat, cure, or prevent any disease and is not a substitute for veterinary care, but supports hydration and normal stool quality.

How does Neonorm Dog fit into Jaguar Health’s Neonorm franchise and strategy?

Neonorm Dog extends Jaguar Health’s Neonorm franchise, which includes Neonorm Foal and Neonorm Calf for pre-weaned animals. According to Jaguar Health, the launch aims to broaden its commercial footprint in the companion animal market and increase brand awareness among pet owners and veterinarians.